Natus has acquired all outstanding shares of NeuroCom capital stock for $18 million, exclusive of direct costs of the acquisition. Natus believes that the acquisition will be immediately accretive to earnings, excluding associated one-time charges.
The acquisition is said to add to Natus’s growth opportunities by broadening its product offerings in the company’s neurology business.
Jim Hawkins, president and CEO of Natus, said: “This acquisition expands our neurology footprint into the growing balance and mobility assessment market. We are very excited about the growth opportunities in this developing field and we believe NeuroCom products can become the standard of care in this emerging field.”